Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
30 Sep 2022
Historique:
entrez: 7 10 2022
pubmed: 8 10 2022
medline: 8 10 2022
Statut: epublish

Résumé

Memory B cells (MBCs) generate rapid antibody responses upon secondary encounter with a pathogen. Here, we investigated the kinetics, avidity and cross-reactivity of serum antibodies and MBCs in 155 SARS-CoV-2 infected and vaccinated individuals over a 16-month timeframe. SARS-CoV-2-specific MBCs and serum antibodies reached steady-state titers with comparable kinetics in infected and vaccinated individuals. Whereas MBCs of infected individuals targeted both pre- and postfusion Spike (S), most vaccine-elicited MBCs were specific for prefusion S, consistent with the use of prefusion-stabilized S in mRNA vaccines. Furthermore, a large fraction of MBCs recognizing postfusion S cross-reacted with human betacoronaviruses. The avidity of MBC-derived and serum antibodies increased over time resulting in enhanced resilience to viral escape by SARS-CoV-2 variants, including Omicron BA.1 and BA.2 sub-lineages, albeit only partially for BA.4 and BA.5 sublineages. Overall, the maturation of high-affinity and broadly-reactive MBCs provides the basis for effective recall responses to future SARS-CoV-2 variants.

Identifiants

pubmed: 36203553
doi: 10.1101/2022.09.30.509852
pmc: PMC9536037
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : DP1 AI158186
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201700059C
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Science. 2022 Aug 19;377(6608):890-894
pubmed: 35857529
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243
pubmed: 32269081
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
Science. 2021 Sep 03;373(6559):1109-1116
pubmed: 34344823
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Sci Immunol. 2022 Dec 23;7(78):eadf1421
pubmed: 36356052
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Nature. 2021 Apr;592(7853):283-289
pubmed: 33524990
Nature. 2021 Oct;598(7880):342-347
pubmed: 34464958
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Science. 2022 Nov 11;378(6620):619-627
pubmed: 36264829
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Nature. 2021 Sep;597(7874):97-102
pubmed: 34261126
Cell. 2022 Apr 28;185(9):1588-1601.e14
pubmed: 35413241
Immunity. 2021 Dec 14;54(12):2893-2907.e5
pubmed: 34614412
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Eur J Immunol. 2009 May;39(5):1260-70
pubmed: 19404981
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Cell Rep. 2021 Mar 23;34(12):108890
pubmed: 33713594
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2022 Feb 25;375(6583):864-868
pubmed: 35076256
Science. 2021 Mar 25;:
pubmed: 33766944
Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6
pubmed: 33975009
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Cell. 2022 May 26;185(11):1875-1887.e8
pubmed: 35523182

Auteurs

Roberta Marzi (R)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Jessica Bassi (J)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Chiara Silacci-Fregni (C)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Istvan Bartha (I)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Francesco Muoio (F)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Katja Culap (K)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Nicole Sprugasci (N)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Gloria Lombardo (G)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Christian Saliba (C)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Elisabetta Cameroni (E)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Antonino Cassotta (A)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.

Jun Siong Low (JS)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.

Alexandra C Walls (AC)

Department of Biochemistry, University of Washington, Seattle, WA, United States of America.

Matthew McCallum (M)

Department of Biochemistry, University of Washington, Seattle, WA, United States of America.

M Alejandra Tortorici (MA)

Department of Biochemistry, University of Washington, Seattle, WA, United States of America.

John E Bowen (JE)

Department of Biochemistry, University of Washington, Seattle, WA, United States of America.

Exequiel A Dellota (EA)

Vir Biotechnology, San Francisco, CA, United States of America.

Josh R Dillen (JR)

Vir Biotechnology, San Francisco, CA, United States of America.

Nadine Czudnochowski (N)

Vir Biotechnology, San Francisco, CA, United States of America.

Laura Pertusini (L)

Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.

Tatiana Terrot (T)

Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.

Valentino Lepori (V)

Independent physician, Bellinzona, Switzerland.

Maciej Tarkowski (M)

III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.

Agostino Riva (A)

III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.

Maira Biggiogero (M)

Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.

Alessandra Franzetti Pellanda (AF)

Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.

Christian Garzoni (C)

Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.

Paolo Ferrari (P)

Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Clinical School, University of New South Wales, Sydney, Australia.

Alessandro Ceschi (A)

Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Science of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.

Olivier Giannini (O)

Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Colin Havenar-Daughton (C)

Vir Biotechnology, San Francisco, CA, United States of America.

Amalio Telenti (A)

Vir Biotechnology, San Francisco, CA, United States of America.

Ann Arvin (A)

Vir Biotechnology, San Francisco, CA, United States of America.

Herbert W Virgin (HW)

Vir Biotechnology, San Francisco, CA, United States of America.
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, United States of America.
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States of America.

Federica Sallusto (F)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Institute of Microbiology, ETH Zurich, Zurich, Switzerland.

David Veesler (D)

Department of Biochemistry, University of Washington, Seattle, WA, United States of America.

Antonio Lanzavecchia (A)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Davide Corti (D)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Luca Piccoli (L)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Classifications MeSH